A phase II study of spirogermanium as second line therapy in patients with poor prognosis lymphoma. An NCI Canada Clinical Trials Group Study.

Abstract	The National Cancer Institute of Canada Clinical Trials Group conducted a phase II study of spirogermanium given daily for 5 days every 3 weeks to patients with poor prognosis non-Hodgkin's lymphomas. All patients had had a maximum of one prior treatment regimen. No responses were seen in 13 evaluable patients. Toxicity was primarily neurologic and mild or moderate in most patients. There is no evidence of activity of spirogermanium given in this schedule in this subset of lymphoma patients.
Authors	E Eisenhauer, I Quirt, J M Connors, J Maroun, J Skillings
Journal	Investigational new drugs (Invest New Drugs) Vol. 3 Issue 3 Pg. 307-10 ( 1985) ISSN: 0167-6997 [Print] United States
PMID	4066225 (Publication Type: Journal Article)
Chemical References	Antineoplastic Agents Organometallic Compounds Spiro Compounds Germanium spirogermanium
Topics	Aged Antineoplastic Agents (adverse effects, therapeutic use) Drug Evaluation Germanium (adverse effects, therapeutic use) Humans Lymphoma (drug therapy) Middle Aged Nervous System Diseases (chemically induced) Organometallic Compounds Prognosis Spiro Compounds (adverse effects, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!